{"id":{"repo_id":"utahstate","oai_identifier":"oai:digitalcommons.usu.edu:etd-3076"},"canonical_url":"https://search.ndltd.org/etd/utahstate/oai:digitalcommons.usu.edu:etd-3076","repository":{"repo_id":"utahstate","name":"Utah State University","base_url":"https://digitalcommons.usu.edu/do/oai/"},"display":{"title":"Novel Aminoglycosides: Bioactive Properties and Mechanism of Action","abstract":"More than 90% of crop diseases are due to fungal infections, which globally cause enormous economic losses. Fungal infections in humans and animals have also become a serious concern, especially in immunocompromised individuals. However, only a few new fungicides have been introduced since the mid-1980s, and concerns with inconsistent and declining effectiveness due to resistance, environmental impacts, animal and human toxicity, and costs continue to challenge the use of available fungicides. There is a serious and persistent need for new antifungal agents that are more effective, eco-friendly, less toxic, and available at reasonable cost. This study reveals two novel aminoglycosides, FG08 and K20, that are synthesized from kanamycin B and A, respectively. Kanamycin B and A are aminoglycoside antibiotics that kill bacteria. In contrast, FG08 and K20 showed broad-spectrum antifungal activities against a wide range of agriculturally and clinically important fungal pathogens, but they did not inhibit bacteria. They showed no or lowered toxicities against animal cells at their antifungal minimum inhibitory concentrations (MICs). They inhibit fungi by interacting with the fungal plasma membrane, leading to pore formation. K20 can be produced on a large scale, which makes it feasible to develop as a fungicide for commercial application. Additionally, K20 showed synergistic antifungal interaction with azoles against various fungi. Azoles are today’s most widely used antifungal agents to treat fungal infections in agriculture and medicine. In conclusion, this research has helped discover a new class of broad spectrum fungicides, which appear attractive for application as crop disease protectants and therapeutics against serious fungal infections in immunocompromised humans.","abstract_html":"More than 90% of crop diseases are due to fungal infections, which globally cause enormous economic losses. Fungal infections in humans and animals have also become a serious concern, especially in immunocompromised individuals. However, only a few new fungicides have been introduced since the mid-1980s, and concerns with inconsistent and declining effectiveness due to resistance, environmental impacts, animal and human toxicity, and costs continue to challenge the use of available fungicides. There is a serious and persistent need for new antifungal agents that are more effective, eco-friendly, less toxic, and available at reasonable cost. This study reveals two novel aminoglycosides, FG08 and K20, that are synthesized from kanamycin B and A, respectively. Kanamycin B and A are aminoglycoside antibiotics that kill bacteria. In contrast, FG08 and K20 showed broad-spectrum antifungal activities against a wide range of agriculturally and clinically important fungal pathogens, but they did not inhibit bacteria. They showed no or lowered toxicities against animal cells at their antifungal minimum inhibitory concentrations (MICs). They inhibit fungi by interacting with the fungal plasma membrane, leading to pore formation. K20 can be produced on a large scale, which makes it feasible to develop as a fungicide for commercial application. Additionally, K20 showed synergistic antifungal interaction with azoles against various fungi. Azoles are today’s most widely used antifungal agents to treat fungal infections in agriculture and medicine. In conclusion, this research has helped discover a new class of broad spectrum fungicides, which appear attractive for application as crop disease protectants and therapeutics against serious fungal infections in immunocompromised humans.","abstract_has_math":false,"creators":["Shrestha, Sanjib K."],"institution":"Hosted by Utah State University Libraries","degree_name":"Doctor of Philosophy (PhD)","degree_level":"Dissertation","degree_discipline":"Biology","degree_department":null,"school":null,"contributors":["Jon Y. Takemoto"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T08:53:37Z","subjects":["aminoglycosides","bioactive","Biology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.doi","label":"DOI","values":["https://doi.org/10.26076/4040-9923"],"render_values":[{"text":"https://doi.org/10.26076/4040-9923","href":"https://doi.org/10.26076/4040-9923","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usu.edu/etd/2073","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usu.edu/etd/2073","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usu.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usu.edu%3Aetd-3076","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Jon Y. Takemoto"]},{"key":"dc:creator","label":"Author","values":["Shrestha, Sanjib K."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2010-01-01T08:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2013-05-01T07:00:00Z"]},{"key":"dc:publisher","label":"Institution","values":["Hosted by Utah State University Libraries"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biology"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (PhD)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["aminoglycosides","bioactive","Biology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usu.edu/etd/2073"]},{"key":"dc:identifier.doi","label":"DOI","values":["https://doi.org/10.26076/4040-9923"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["More than 90% of crop diseases are due to fungal infections, which globally cause enormous economic losses. Fungal infections in humans and animals have also become a serious concern, especially in immunocompromised individuals. However, only a few new fungicides have been introduced since the mid-1980s, and concerns with inconsistent and declining effectiveness due to resistance, environmental impacts, animal and human toxicity, and costs continue to challenge the use of available fungicides. There is a serious and persistent need for new antifungal agents that are more effective, eco-friendly, less toxic, and available at reasonable cost. This study reveals two novel aminoglycosides, FG08 and K20, that are synthesized from kanamycin B and A, respectively. Kanamycin B and A are aminoglycoside antibiotics that kill bacteria. In contrast, FG08 and K20 showed broad-spectrum antifungal activities against a wide range of agriculturally and clinically important fungal pathogens, but they did not inhibit bacteria. They showed no or lowered toxicities against animal cells at their antifungal minimum inhibitory concentrations (MICs). They inhibit fungi by interacting with the fungal plasma membrane, leading to pore formation. K20 can be produced on a large scale, which makes it feasible to develop as a fungicide for commercial application. Additionally, K20 showed synergistic antifungal interaction with azoles against various fungi. Azoles are today’s most widely used antifungal agents to treat fungal infections in agriculture and medicine. In conclusion, this research has helped discover a new class of broad spectrum fungicides, which appear attractive for application as crop disease protectants and therapeutics against serious fungal infections in immunocompromised humans."]},{"key":"dc:title","label":"Title","values":["Novel Aminoglycosides: Bioactive Properties and Mechanism of Action"]}]}],"canonical_facts":{"dc:contributor":["Jon Y. Takemoto"],"dc:creator":["Shrestha, Sanjib K."],"dc:date.available":["2010-01-01T08:00:00Z"],"dc:date.created":["2013-05-01T07:00:00Z"],"dc:description.abstract":["More than 90% of crop diseases are due to fungal infections, which globally cause enormous economic losses. Fungal infections in humans and animals have also become a serious concern, especially in immunocompromised individuals. However, only a few new fungicides have been introduced since the mid-1980s, and concerns with inconsistent and declining effectiveness due to resistance, environmental impacts, animal and human toxicity, and costs continue to challenge the use of available fungicides. There is a serious and persistent need for new antifungal agents that are more effective, eco-friendly, less toxic, and available at reasonable cost. This study reveals two novel aminoglycosides, FG08 and K20, that are synthesized from kanamycin B and A, respectively. Kanamycin B and A are aminoglycoside antibiotics that kill bacteria. In contrast, FG08 and K20 showed broad-spectrum antifungal activities against a wide range of agriculturally and clinically important fungal pathogens, but they did not inhibit bacteria. They showed no or lowered toxicities against animal cells at their antifungal minimum inhibitory concentrations (MICs). They inhibit fungi by interacting with the fungal plasma membrane, leading to pore formation. K20 can be produced on a large scale, which makes it feasible to develop as a fungicide for commercial application. Additionally, K20 showed synergistic antifungal interaction with azoles against various fungi. Azoles are today’s most widely used antifungal agents to treat fungal infections in agriculture and medicine. In conclusion, this research has helped discover a new class of broad spectrum fungicides, which appear attractive for application as crop disease protectants and therapeutics against serious fungal infections in immunocompromised humans."],"dc:identifier":["https://digitalcommons.usu.edu/etd/2073"],"dc:identifier.doi":["https://doi.org/10.26076/4040-9923"],"dc:publisher":["Hosted by Utah State University Libraries"],"dc:subject":["aminoglycosides","bioactive","Biology"],"dc:title":["Novel Aminoglycosides: Bioactive Properties and Mechanism of Action"],"thesis:degree_discipline":["Biology"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Doctor of Philosophy (PhD)"]},"updated_at":"2026-11-19T08:53:37Z"}